Abonnement à la biblothèque: Guest
Critical Reviews™ in Therapeutic Drug Carrier Systems

Publication de 6  numéros par an

ISSN Imprimer: 0743-4863

ISSN En ligne: 2162-660X

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.7 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 3.6 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.8 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00023 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.39 SJR: 0.42 SNIP: 0.89 CiteScore™:: 5.5 H-Index: 79

Indexed in

Particulate Pulmonary Delivery Systems Containing Anti-Tuberculosis Agents

Volume 30, Numéro 4, 2013, pp. 277-291
DOI: 10.1615/CritRevTherDrugCarrierSyst.2013005684
Get accessGet access

RÉSUMÉ

There is renewed interest in delivering anti-tuberculosis (TB) drugs to the lungs by inhalation. Several groups have investigated particulate pulmonary drug delivery formulations containing anti-TB agents, prepared using a variety of design approaches and processes. This review summarizes trends that indicate feasibility and translation of research efforts aimed at developing inhaled therapies for TB. Whereas formulations intended for reconstitution as solutions prior to nebulization can be produced with relative ease, particle engineering for powder formulations is more specialized. Spray drying and emulsion methods used to prepare particulate pulmonary delivery systems of anti-TB agents are compared. Pharmaceutical characterization is outlined. Administration of repeated inhalations to laboratory animals, especially under Animal Biosafety Level-3 (ABSL-3) containment as required for TB research, is another major challenge. Techniques employed by different groups are reviewed in the context of suitability for drug delivery and amenability towards use in ABSL-3 settings. It is concluded that spray drying is suitable for production of inhalable particles, rigorous physicochemical characterization is necessary for developing inhaled therapies as drug products, and pulmonary delivery of formulations containing anti-TB drugs to animals infected with Mycobacterium tuberculosis can best be carried out using handheld devices.

CITÉ PAR
  1. Paranjpe Mukta, Müller-Goymann Christel, Nanoparticle-Mediated Pulmonary Drug Delivery: A Review, International Journal of Molecular Sciences, 15, 4, 2014. Crossref

  2. Abedon Stephen T, Phage therapy of pulmonary infections, Bacteriophage, 5, 1, 2015. Crossref

  3. Giovagnoli Stefano, Schoubben Aurélie, Rossi Carlo, Ion Pairing for Controlling Drug Delivery, in Drug Delivery Systems for Tuberculosis Prevention and Treatment, 2016. Crossref

  4. Wong Jennifer, Ricci Maurizio, Chan Hak-Kim, Spray Drying Strategies to Stop Tuberculosis, in Drug Delivery Systems for Tuberculosis Prevention and Treatment, 2016. Crossref

  5. Giovagnoli Stefano, Schoubben Aurelie, Ricci Maurizio, The long and winding road to inhaled TB therapy: not only the bug’s fault, Drug Development and Industrial Pharmacy, 43, 3, 2017. Crossref

  6. Rawal Tejal, Parmar Rajesh, Tyagi Rajeev K., Butani Shital, Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis, Colloids and Surfaces B: Biointerfaces, 154, 2017. Crossref

  7. Kunda Nitesh, Price Dominique, Muttil Pavan, Respiratory Tract Deposition and Distribution Pattern of Microparticles in Mice Using Different Pulmonary Delivery Techniques, Vaccines, 6, 3, 2018. Crossref

  8. Rawal Tejal, Patel Snehal, Butani Shital, Chitosan nanoparticles as a promising approach for pulmonary delivery of bedaquiline, European Journal of Pharmaceutical Sciences, 124, 2018. Crossref

  9. Eedara Basanth Babu, Rangnekar Bhamini, Doyle Colin, Cavallaro Alex, Das Shyamal C., The influence of surface active l-leucine and 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC) in the improvement of aerosolization of pyrazinamide and moxifloxacin co-spray dried powders, International Journal of Pharmaceutics, 542, 1-2, 2018. Crossref

  10. Rangnekar Bhamini, Momin Mohammad A.M., Eedara Basanth Babu, Sinha Shubhra, Das Shyamal C., Bedaquiline containing triple combination powder for inhalation to treat drug-resistant tuberculosis, International Journal of Pharmaceutics, 570, 2019. Crossref

  11. d'Angelo Ivana, Quaglia Fabiana, Ungaro Francesca, PLGA carriers for inhalation: where do we stand, where are we headed?, Therapeutic Delivery, 6, 10, 2015. Crossref

  12. Rath Goutam, Pradhan Deepak, Ghosh Goutam, Goyal Amit K., Challenges and Opportunities of Nanotechnological based Approach for the Treatment of Tuberculosis, Current Pharmaceutical Design, 27, 17, 2021. Crossref

Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections Prix et politiques d'abonnement Begell House Contactez-nous Language English 中文 Русский Português German French Spain